

Mignon L Loh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9143829/publications.pdf>

Version: 2024-02-01

389
papers

27,767
citations

4388

86
h-index

6836

155
g-index

398
all docs

398
docs citations

398
times ranked

22439
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. <i>Haematologica</i> , 2023, 108, 717-731.	3.5	6
2	CD22 ^{low} /Bcl-2 ^{high} expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 251-255.	5.2	4
3	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	1.4	28
4	Molecular and phenotypic diversity of CBL/I -mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2022, 107, 178-186.	3.5	25
5	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	7.2	14
6	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2022, 8, 354.	7.1	35
7	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. <i>Journal of Clinical Oncology</i> , 2022, 40, 956-967.	1.6	42
8	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. <i>Nature Genetics</i> , 2022, 54, 170-179.	21.4	29
9	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	4.1	12
10	Outstanding outcomes in infants with $\text{KMT2A}/\text{I}$ -germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	3.5	11
11	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
12	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	7.2	6
13	Molecular Mechanisms of ARID5B -Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1287-1295.	6.3	10
14	Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1167-1175.	6.3	6
15	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 10023-10023.	1.6	1
16	Abstract 2002: A genome-wide association study identifies novel sepsis risk loci in children with Down syndrome-associated acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Cancer Research</i> , 2022, 82, 2002-2002.	0.9	0
17	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.	1.6	0
18	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	1.4	814

#	ARTICLE	IF	CITATIONS
19	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	1.2	30
20	Genome-Wide Association Study of Susceptibility Loci for <i>TCF3-PBX1</i> Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2021, 113, 933-937.	6.3	9
21	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	1.4	3
22	Molecular basis of <i>ETV6</i> -mediated predisposition to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 364-373.	1.4	37
23	SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. <i>Blood</i> , 2021, 137, 1835-1838.	1.4	6
24	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 168-177.	1.4	35
25	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	6.3	16
26	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
27	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2021, 8, e55-e66.	4.6	32
28	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. <i>Leukemia</i> , 2021, 35, 1279-1290.	7.2	46
29	The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment. <i>Haematologica</i> , 2021, 106, 2242-2245.	3.5	3
30	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
31	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	1.5	9
32	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
33	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. <i>Leukemia</i> , 2021, 35, 3272-3277.	7.2	40
34	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 833.	7.4	177
35	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	4.7	7
36	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	1.6	56

#	ARTICLE	IF	CITATIONS
37	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	1.6	19
38	Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. <i>Leukemia</i> , 2021, , .	7.2	9
39	Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2846-2867.	9.4	83
40	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. <i>Blood Advances</i> , 2021, 5, 2890-2900.	5.2	3
41	Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2990-2994.	3.5	6
42	Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1521-1528.	7.1	5
43	<i>Nf1</i> and <i>Sh2b3</i> mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021, 5, 3587-3591.	5.2	1
44	Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. <i>Blood Advances</i> , 2021, 5, 4783-4793.	5.2	13
45	JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1 β . <i>Blood Advances</i> , 2021, , .	5.2	3
46	ALL-167: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Have the T315I Mutation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S271-S272.	0.4	0
47	Germline <i>RUNX1</i> variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
48	Poster: ALL-144: Oncogenic Deregulation of <i>BCL11B</i> in Lineage Ambiguous Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S207.	0.4	0
49	Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021, 5, 5507-5518.	5.2	4
50	International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 158-168.	7.0	35
51	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021, 138, 2382-2382.	1.4	0
52	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3487-3487.	1.4	1
53	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3476-3476.	1.4	0
54	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2021, 138, 363-363.	1.4	8

#	ARTICLE	IF	CITATIONS
55	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 614-614.	1.4	1
56	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.	1.4	10
57	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. <i>Blood</i> , 2021, 138, 3679-3679.	1.4	4
58	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021, 138, 3398-3398.	1.4	3
59	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2021, 138, 211-211.	1.4	3
60	Fusion driven JMML: a novel CCDC88Câ€“FLT3 fusion responsive to sorafenib identified by RNA sequencing. <i>Leukemia</i> , 2020, 34, 662-666.	7.2	27
61	Mixedâ€“phenotype acute leukemia: A cohort and consensus research strategy from the Childrenâ€™s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	4.1	32
62	Advancing <sc>RAS/RASopathy</sc> therapies: An NCIâ€“sponsored intramural and extramural collaboration for the study of <sc>RASopathies</sc>. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 866-876.	1.2	40
63	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020, 38, 602-612.	1.6	107
64	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. <i>Cancer Research</i> , 2020, 80, 5189-5202.	0.9	9
65	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 1113-1127.	13.2	32
66	Childrenâ€™s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	1.6	136
67	The COVIDâ€“19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOPâ€“, SIOPâ€“PODC, IPSO, PROS, CCI, and St Jude Global. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28409.	1.5	113
68	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Contextâ€“Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. <i>Molecular Cancer Research</i> , 2020, 18, 1153-1165.	3.4	20
69	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Childrenâ€™s Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	1.6	41
70	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Childrenâ€™s Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	1.6	42
71	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 1897-1905.	1.6	117
72	Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study. <i>Blood</i> , 2020, 136, 16-17.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. <i>Blood</i> , 2020, 136, 20-21.	1.4	5
74	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10509-10509.	1.6	3
75	Abstract 5399: The NSD2 p.E1099K mutation is enriched at relapse and confers drug resistance in a cell context dependent manner in pediatric acute lymphoblastic leukemia. , 2020, , .		1
76	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	1.4	1
77	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2020, 136, 47-47.	1.4	0
78	Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
79	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 39-40.	1.4	2
80	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. <i>Blood</i> , 2020, 136, 37-38.	1.4	8
81	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 38-39.	1.4	0
82	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. <i>Leukemia</i> , 2019, 33, 181-190.	7.2	43
83	Genetic characterization and therapeutic targeting of <i>MYC</i> -rearranged T cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 169-174.	2.5	9
84	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.4	32
85	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. <i>Blood</i> , 2019, 134, 1227-1237.	1.4	37
86	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27948.	1.5	13
87	Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27905.	1.5	7
88	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2019, 14, e0221288.	2.5	16
89	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019, 60, 1740-1748.	1.3	25
90	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	3.5	11

#	ARTICLE	IF	CITATIONS
91	Epigenetic silencing of <i>SOCS5</i> potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 1931-1946.	3.9	24
92	Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2019, 79, 2339-2351.	0.9	55
93	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	1.5	8
94	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019, 51, 694-704.	21.4	97
95	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 780-789.	1.6	48
96	Case report: Impact of BITE on CAR-T cell expansion. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e50.	0.9	7
97	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. <i>Nature Communications</i> , 2019, 10, 5348.	12.8	58
98	Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. <i>Leukemia</i> , 2019, 33, 671-685.	7.2	12
99	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	3.5	25
100	<i>Phf6</i> Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. <i>Cancer Discovery</i> , 2019, 9, 436-451.	9.4	67
101	Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1125-1137.	6.4	38
102	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	21.4	384
103	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	1.4	44
104	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 884-892.	7.2	158
105	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. <i>Blood</i> , 2019, 134, 652-652.	1.4	6
106	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. <i>Blood</i> , 2019, 134, 741-741.	1.4	36
107	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. <i>Blood</i> , 2019, 134, 2649-2649.	1.4	12
108	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. <i>Blood</i> , 2019, 134, 1293-1293.	1.4	4

#	ARTICLE	IF	CITATIONS
109	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2019, 134, LBA-1-LBA-1.	1.4	51
110	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. <i>Journal of Clinical Oncology</i> , 2019, 37, 10008-10008.	1.6	31
111	Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2019, 134, 650-650.	1.4	0
112	RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3947-3947.	1.4	1
113	DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation. <i>Blood</i> , 2019, 134, 1693-1693.	1.4	0
114	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in <i>Pseudomonas Fluorescens</i> (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to <i>Escherichia coli</i> -Derived Asparaginases. <i>Blood</i> , 2019, 134, 2586-2586.	1.4	0
115	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018, 32, 1370-1379.	7.2	40
116	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2126-2137.	7.2	48
117	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	16.8	142
118	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. <i>Future Oncology</i> , 2018, 14, 2115-2129.	2.4	47
119	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27062.	1.5	48
120	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. <i>Nature</i> , 2018, 553, 511-514.	27.8	90
121	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018, 124, 1150-1159.	4.1	46
122	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26928.	1.5	28
123	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018, 131, 1350-1359.	1.4	158
124	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	1.4	170
125	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27034.	1.5	26
126	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26873.	1.5	48

#	ARTICLE	IF	CITATIONS
127	Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. <i>Cancer</i> , 2018, 124, 571-579.	4.1	31
128	Severe pegaspargase hypersensitivity reaction rates (grade ≥ 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 1624-1633.	1.3	37
129	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	1.6	185
130	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	1.6	121
131	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	8.5	37
132	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	1.6	164
133	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. <i>JCI Insight</i> , 2018, 3, .	5.0	71
134	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	27.8	236
135	Characterization of PAX5-driven Subtypes in B-progenitor Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S183.	0.4	3
136	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. <i>Biomarker Research</i> , 2018, 6, 27.	6.8	9
137	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018, 2, 529-533.	5.2	34
138	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. <i>SLAS Discovery</i> , 2018, 23, 732-741.	2.7	5
139	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018, 132, 815-824.	1.4	97
140	Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. <i>Stem Cell Research</i> , 2018, 31, 157-160.	0.7	11
141	Using genomics to define pediatric blood cancers and inform practice. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 286-300.	2.5	6
142	A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. <i>Blood</i> , 2018, 132, 555-555.	1.4	42
143	Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331. <i>Blood</i> , 2018, 132, 1382-1382.	1.4	8
144	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018, 132, 1000-1000.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	1.4	7
146	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. <i>Blood</i> , 2018, 132, 1405-1405.	1.4	5
147	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	1.4	3
148	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	1.4	14
149	Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4026-4026.	1.4	1
150	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018, 132, 659-659.	1.4	0
151	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 177-187.	1.4	138
152	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, e26-e37.	1.4	195
153	Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 3000-3008.	1.4	48
154	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	1.4	236
155	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017, 130, 397-407.	1.4	112
156	Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. <i>Clinical Cancer Research</i> , 2017, 23, 5329-5338.	7.0	21
157	Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 2064-2072.	1.4	198
158	Dysregulation of the transcription factor runx1 in juvenile myelomonocytic leukemia. <i>Experimental Hematology</i> , 2017, 53, S51.	0.4	0
159	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	21.4	693
160	Klinefelter syndrome and 47,XY syndrome in children with B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 843-846.	2.5	4
161	Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. <i>Clinical Cancer Research</i> , 2017, 23, 1852-1861.	7.0	29
162	Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2017, , .	7.2	1

#	ARTICLE	IF	CITATIONS
163	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2127.	12.8	75
164	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2700-2707.	1.6	38
165	Reply to I.J. Cohen. <i>Journal of Clinical Oncology</i> , 2017, 35, 3989-3991.	1.6	2
166	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	1.6	64
167	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq1 11017843143gBT /O	1.6	43
168	Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. <i>Blood Advances</i> , 2017, 1, 1657-1671.	5.2	76
169	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2017, 130, 883-883.	1.4	2
170	Ph-like acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 561-566.	2.5	57
171	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. <i>Nature Communications</i> , 2016, 7, 10635.	12.8	44
172	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	1.6	301
173	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2133-2140.	1.6	88
174	Pediatric MDS: GATA screen the germline. <i>Blood</i> , 2016, 127, 1377-1378.	1.4	5
175	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016, 127, 558-564.	1.4	56
176	Characterization of leukemias with ETV6-ABL1 fusion. <i>Haematologica</i> , 2016, 101, 1082-1093.	3.5	66
177	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11306-11311.	7.1	151
178	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	12.8	218
179	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	21.4	231
180	Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. <i>Nature</i> , 2016, 539, 304-308.	27.8	210

#	ARTICLE	IF	CITATIONS
181	Germline <i>RRAS2</i> mutations are not associated with Noonan syndrome. <i>Journal of Medical Genetics</i> , 2016, 53, 728-728.	3.2	6
182	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <scp>AALL0331</scp>. <i>International Journal of Cancer</i> , 2016, 138, 332-339.	5.1	66
183	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. <i>Nature Communications</i> , 2016, 7, 10647.	12.8	15
184	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2016, 29, 186-200.	16.8	118
185	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016, 128, 1085-1085.	1.4	1
186	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016, 128, 1086-1086.	1.4	2
187	BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 280-280.	1.4	5
188	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. <i>Blood</i> , 2016, 128, 39-39.	1.4	2
189	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. <i>Blood</i> , 2016, 128, 3965-3965.	1.4	5
190	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 451-451.	1.4	4
191	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016, 128, 454-454.	1.4	4
192	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	1.4	1
193	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	1.4	1
194	Targeting JAK Pathway-Mutant Acute Lymphoblastic Leukemia. , 2016, 13, .		0
195	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. <i>Blood</i> , 2016, 128, 4083-4083.	1.4	0
196	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	1.4	0
197	Improved Diagnosis of Intrachromosomal Amplification of Chromosome 21 (iAMP21) By Copy Number Profiling. <i>Blood</i> , 2016, 128, 1733-1733.	1.4	0
198	RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2016, 128, 2699-2699.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 455-455.	1.4	1
200	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. <i>Blood</i> , 2016, 128, 1739-1739.	1.4	0
201	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , 2016, 128, 1729-1729.	1.4	0
202	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 414-418.	1.5	31
203	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015, 125, 680-686.	1.4	110
204	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	1.4	287
205	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 17-22.	3.5	43
206	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. <i>Cancer</i> , 2015, 121, 3577-3590.	4.1	59
207	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 629-636.	1.5	43
208	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). <i>Pediatric Blood and Cancer</i> , 2015, 62, 1717-1724.	1.5	103
209	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	1.5	76
210	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 516-524.	1.4	69
211	Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 364-374.	4.1	49
212	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	16.8	109
213	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015, 6, 7553.	12.8	72
214	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1759-1767.	1.4	189
215	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 815.	7.4	234
216	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015, 521, 357-361.	27.8	127

#	ARTICLE	IF	CITATIONS
217	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6604.	12.8	281
218	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	10.7	161
219	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	21.4	233
220	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genetics, 2015, 208, 1-18.	0.4	30
221	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR) Tj ETQq1 1 0.784314 rgBT /Over 1.4 1303-1303.	1.4	1
222	Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1423-1423.	1.4	1
223	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. Blood, 2015, 126, 2502-2502.	1.4	8
224	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3765-3765.	1.4	3
225	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. Blood, 2015, 126, 3792-3792.	1.4	11
226	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood, 2015, 126, 691-691.	1.4	4
227	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	1.4	1
228	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2015, 126, 694-694.	1.4	2
229	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. Blood, 2015, 126, 794-794.	1.4	12
230	Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 798-798.	1.4	4
231	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood, 2015, 126, 807-807.	1.4	5
232	Cbly371H Transgene Combined with Hematopoietic Deletion of the Endogenous c-Cbl Gene Results in GM-CSF Hypersensitivity and Leukocytosis. Blood, 2015, 126, 3672-3672.	1.4	0
233	Characterization of Leukemias with ETV6-ABL1 Fusion. Blood, 2015, 126, 84-84.	1.4	1
234	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	1.4	2

#	ARTICLE	IF	CITATIONS
235	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 556-556.	1.4	0
236	Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. <i>Human Molecular Genetics</i> , 2014, 23, 4315-4327.	2.9	114
237	Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation. <i>Frontiers in Pediatrics</i> , 2014, 2, 25.	1.9	43
238	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	1.6	91
239	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	12.6	665
240	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	9.4	201
241	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	27.0	1,161
242	Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of <i>IGH</i>. <i>Clinical Cancer Research</i> , 2014, 20, 4540-4548.	7.0	138
243	Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. <i>Blood</i> , 2014, 124, 2487-2497.	1.4	98
244	PI3K p110 β uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. <i>Blood</i> , 2014, 123, 2838-2842.	1.4	35
245	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. <i>Blood</i> , 2014, 123, 1426-1427.	1.4	12
246	A New System Identification Approach to Identify Genetic Variants in Sequencing Studies for a Binary Phenotype. <i>Human Heredity</i> , 2014, 78, 104-116.	0.8	19
247	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 1-1.	1.4	113
248	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 3649-3649.	1.4	5
249	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014, 124, 367-367.	1.4	1
250	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 786-786.	1.4	3
251	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014, 124, 793-793.	1.4	15
252	Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2014, 124, 410-410.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 612-612.	1.4	0
254	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	1.4	6
255	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3570-3570.	1.4	0
256	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 128-128.	1.4	0
257	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 284-284.	1.4	0
258	Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers. <i>Blood</i> , 2014, 124, 2207-2207.	1.4	0
259	Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (<i>PTPN11</i>). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7212-7221.	6.4	57
260	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 4925-4929.	1.4	104
261	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. <i>Blood</i> , 2013, 121, 485-488.	1.4	156
262	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 957-963.	1.5	149
263	High-Throughput Sequencing to Detect Minimal Residual Disease in Acute T Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S369.	0.4	3
264	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	21.4	264
265	Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of <i>PTPN11</i>-Associated Malignancies. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1738-1748.	4.1	41
266	Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis. <i>Science Signaling</i> , 2013, 6, ra21.	3.6	45
267	Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia. <i>Cancer Research</i> , 2013, 73, 2540-2550.	0.9	23
268	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 733-742.	6.3	208
269	Genetic predispositions to childhood leukemia. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 270-290.	2.5	68
270	Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 3397-3402.	1.6	125

#	ARTICLE	IF	CITATIONS
271	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 242-252.	21.4	588
272	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. <i>Blood</i> , 2013, 121, 1814-1818.	1.4	102
273	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013, 121, 898-904.	1.4	174
274	Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachmanâ€”Diamond syndrome. <i>Pediatric Blood and Cancer</i> , 2013, 60, 754-760.	1.5	22
275	GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure. <i>Blood</i> , 2013, 122, 1520-1520.	1.4	3
276	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 232-232.	1.4	8
277	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. <i>Blood</i> , 2013, 122, 2550-2550.	1.4	12
278	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2672-2672.	1.4	5
279	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 3736-3736.	1.4	1
280	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). <i>Blood</i> , 2013, 122, 45-45.	1.4	2
281	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 60-60.	1.4	1
282	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 618-618.	1.4	6
283	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 824-824.	1.4	4
284	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013, 122, 825-825.	1.4	8
285	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€œ or â€œBCR-ABL1-Likeâ€œ) Signature For Therapeutic Targeting and Clinical Intervention. <i>Blood</i> , 2013, 122, 826-826.	1.4	65
286	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Childrenâ€™s Oncology Group (COG) AALL0331. <i>Blood</i> , 2013, 122, 837-837.	1.4	13
287	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. <i>ELife</i> , 2013, 2, e00825.	6.0	32
288	Genomic- and Transcriptomic Profiling Of Acute Lymphoblastic Leukemia With Dicentric Chromosomes. <i>Blood</i> , 2013, 122, 234-234.	1.4	1

#	ARTICLE	IF	CITATIONS
289	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3868-3868.	1.4	0
290	Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2013, 122, 1526-1526.	1.4	0
291	On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. <i>Blood</i> , 2013, 122, 1341-1341.	1.4	19
292	Overexpression Of Leukemia Associated Cbly371H Mutation In Transgenic Mice Causes Dosage Dependent Embryonic Lethality. <i>Blood</i> , 2013, 122, 2515-2515.	1.4	0
293	Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. <i>Blood</i> , 2013, 122, 2628-2628.	1.4	0
294	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 751-757.	1.6	165
295	Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 2754-2767.	7.0	50
296	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. <i>Blood</i> , 2012, 119, 3512-3522.	1.4	210
297	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 833-842.	1.4	201
298	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 3510-3518.	1.4	263
299	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 153-166.	16.8	621
300	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012, 481, 157-163.	27.8	1,430
301	High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2012, 4, 134ra63.	12.4	207
302	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012, 120, 137-137.	1.4	7
303	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012, 120, 2466-2466.	1.4	5
304	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. <i>Blood</i> , 2012, 120, 2529-2529.	1.4	10
305	Clinical Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD): A Distinct Clinical Entity Mimicking Juvenile Myelomonocytic Leukemia (JMML) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2012, 120, 1033-1033.	1.4	0
306	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. <i>Blood</i> , 2012, 120, 1440-1440.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 878-878.	1.4	0
308	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Blood</i> , 2012, 120, 877-877.	1.4	2
309	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 289-289.	1.4	4
310	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. <i>Blood</i> , 2012, 120, 2505-2505.	1.4	0
311	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2011, 118, 3080-3087.	1.4	255
312	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 2191-2199.	1.4	102
313	Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 677-687.	2.5	139
314	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2011, 43, 237-241.	21.4	239
315	Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. <i>Pediatric Blood and Cancer</i> , 2011, 56, 984-993.	1.5	60
316	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2011, 118, 1440-1440.	1.4	3
317	High-Throughput Screening by Flow Cytometry Identifies Reduced Expression of CD48 As a Universal Characteristic of T-ALL and a Suitable Target for Minimal Residual Disease (MRD) Detection. <i>Blood</i> , 2011, 118, 2547-2547.	1.4	6
318	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. <i>Blood</i> , 2011, 118, 743-743.	1.4	3
319	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011, 118, 249-249.	1.4	1
320	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. <i>Blood</i> , 2011, 118, 739-739.	1.4	2
321	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 67-67.	1.4	0
322	Patient-Derived Induced Pluripotent Stem Cells Recapitulate Hematopoietic Abnormalities of Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2011, 118, 637-637.	1.4	0
323	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 68-68.	1.4	0
324	High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 2545-2545.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 421-429.	1.5	97
326	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2010, 42, 794-800.	21.4	308
327	Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 357-362.	2.5	31
328	Absence of Biallelic γ TCR Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	1.6	93
329	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. <i>Blood</i> , 2010, 116, 2752-2752.	1.4	7
330	Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. <i>Blood</i> , 2010, 116, 410-410.	1.4	4
331	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. <i>Blood</i> , 2010, 116, 411-411.	1.4	3
332	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. <i>Blood</i> , 2010, 116, 869-869.	1.4	7
333	Early Response Characteristics and Blast Cytogenetic Features In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. <i>Blood</i> , 2010, 116, 414-414.	1.4	0
334	Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/ β -Catenin. <i>Blood</i> , 2010, 116, 3264-3264.	1.4	0
335	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 8-8.	1.4	1
336	Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3263-3263.	1.4	0
337	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3251-3251.	1.4	0
338	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. <i>Blood</i> , 2010, 116, 315-315.	1.4	7
339	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 865-865.	1.4	2
340	JAK mutations in high-risk childhood acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9414-9418.	7.1	516
341	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. <i>Pediatric Blood and Cancer</i> , 2009, 52, 259-262.	1.5	51
342	A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. <i>Blood</i> , 2009, 113, 1075-1085.	1.4	54

#	ARTICLE	IF	CITATIONS
343	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. <i>Blood</i> , 2009, 114, 1859-1863.	1.4	260
344	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. <i>Blood</i> , 2009, 114, 1580-1580.	1.4	7
345	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. <i>Blood</i> , 2009, 114, 310-310.	1.4	2
346	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. <i>Blood</i> , 2009, 114, 704-704.	1.4	15
347	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. <i>Blood</i> , 2009, 114, 85-85.	1.4	10
348	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of inductionâ€™A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009, 114, 9-9.	1.4	24
349	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. <i>Blood</i> , 2009, 114, 2598-2598.	1.4	6
350	<i>JAK2 V617F</i> positive polycythemia Vera in a child with neurofibromatosis type I. <i>Pediatric Blood and Cancer</i> , 2008, 51, 689-691.	1.5	2
351	<i>SOS1</i> mutations are rare in human malignancies: Implications for Noonan syndrome patients. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 253-259.	2.8	40
352	Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates. <i>Cancer Cell</i> , 2008, 14, 335-343.	16.8	219
353	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. <i>Blood</i> , 2008, 111, 1124-1127.	1.4	33
354	Chromosome 12p Deletions in<i>TEL-AML1</i>Childhood Acute Lymphoblastic Leukemia Are Associated with Retrotransposon Elements and Occur Postnatally. <i>Cancer Research</i> , 2008, 68, 9935-9944.	0.9	26
355	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Childrenâ€™s Oncology Group (COG) Study.. <i>Blood</i> , 2008, 112, 2256-2256.	1.4	0
356	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Childrenâ€™s Oncology Group Trials.. <i>Blood</i> , 2008, 112, 1514-1514.	1.4	0
357	Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. <i>Journal of Clinical Oncology</i> , 2007, 25, 813-819.	1.6	171
358	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	1.4	413
359	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. <i>Blood</i> , 2007, 110, 120-120.	1.4	4
360	A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.. <i>Blood</i> , 2007, 110, 546-546.	1.4	3

#	ARTICLE	IF	CITATIONS
361	Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group.. Blood, 2007, 110, 758-758.	1.4	0
362	Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete) Consortium.. Blood, 2007, 110, 854-854.	1.4	0
363	Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.. Blood, 2007, 110, 2657-2657.	1.4	0
364	A Rare Case of JAK2 V617F Positive Polycythemia Vera in a Child with Neurofibromatosis Type I.. Blood, 2007, 110, 4661-4661.	1.4	0
365	Congenital leukemia cutis with subsequent development of leukemia. Journal of the American Academy of Dermatology, 2006, 54, S22-S27.	1.2	51
366	Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood, 2006, 107, 4508-4513.	1.4	103
367	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107, 2639-2642.	1.4	204
368	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood and Cancer, 2006, 46, 579-585.	1.5	103
369	Factors Influencing Survival after Relapse from Childhood ALL: A Children's Oncology Group Study.. Blood, 2006, 108, 1855-1855.	1.4	4
370	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.. Blood, 2006, 108, 2681-2681.	1.4	3
371	Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research, 2005, 29, 459-462.	0.8	64
372	Pharmacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).. Blood, 2005, 106, 1243-1243.	1.4	2
373	Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children's Oncology Group Study.. Blood, 2005, 106, 2587-2587.	1.4	20
374	Health-Related Quality of Life (HRQL) in Children with Severe, Chronic Immune Thrombocytopenia (cITP) Treated with Rituximab.. Blood, 2005, 106, 5575-5575.	1.4	1
375	Cytogenetics of Hispanics and Whites with Childhood Acute Lymphoblastic Leukemia in California.. Blood, 2005, 106, 4536-4536.	1.4	0
376	Activating Mutations of the Noonan Syndrome-Associated <i>SHP2/PTPN11</i> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 8816-8820.	0.9	472
377	SHP-2 and myeloid malignancies. Current Opinion in Hematology, 2004, 11, 44-50.	2.5	106
378	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103, 2325-2331.	1.4	415

#	ARTICLE	IF	CITATIONS
379	PTPN11 Mutational Spectrum in Juvenile Myelomonocytic Leukemia and Noonan Syndrome.. Blood, 2004, 104, 3417-3417.	1.4	1
380	Functional Analysis of Leukemia-Associated PTPN11 Mutations in Primary Hematopoietic Cells.. Blood, 2004, 104, 2423-2423.	1.4	0
381	Prenatal origin ofTEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosomes and Cancer, 2003, 37, 36-43.	2.8	74
382	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Current Opinion in Hematology, 2002, 9, 345-352.	2.5	61
383	Treatment of Infantile Fibrosarcoma With Chemotherapy and Surgery: Results From the Dana-Farber Cancer Institute and Children's Hospital, Boston. Journal of Pediatric Hematology/Oncology, 2002, 24, 722-726.	0.6	103
384	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell, 2002, 1, 75-87.	16.8	1,024
385	Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2000, 122, 79-82.	1.0	12
386	Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2. Molecular Cell, 2000, 6, 693-704.	9.7	289
387	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics, 1999, 23, 166-175.	21.4	1,036
388	Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1. Leukemia Research, 1998, 22, 461-464.	0.8	12
389	Congenital Fibrosarcoma of the Upper Extremity. Plastic and Reconstructive Surgery, 1998, 102, 1158-1162.	1.4	26